Characteristics and evidence-based management of stable coronary artery disease patients in Canada compared with the rest of the world: insights from the CLARIFY registry.
BACKGROUND
Previous Canadian high vascular risk registries have demonstrated suboptimal goal-directed reductions in cardiovascular risk factors and underutilization of guideline-recommended therapies in part because of physician underestimation of cardiovascular risk.


METHODS
The Prospective Observational Longitudinal Registry of Patients With Stable Coronary Artery Disease (CLARIFY) registry enrolled 33,438 stable coronary artery disease patients in 45 countries. In Canada, supplemental information was obtained specifying reasons that patients were not taking guideline-recommended medications.


RESULTS
In Canada, 1232 patients (9 provinces, 110 physicians) were enrolled and in comparison with the rest of the world, there were several differences in cardiovascular risk factors and medical history; in addition, the Canadian cohort had undergone less percutaneous coronary intervention, but more coronary artery bypass grafting. Among the Canadian cohort, many still continue to smoke (13%) and many do not meet secondary prevention targets for waist circumference (54%), body mass index (81%), physical activity (71%), cholesterol (43%), and systolic blood pressure (20%). Nevertheless, the use of guideline-recommended cardiovascular therapy was high and >90% reported partial/full financial coverage for medications. The number of patients not receiving guideline-recommended therapies because of apparent underestimation of risk was particularly low for antiplatelet agents (2%), β-blockers (11%), and lipid-lowering therapies (1%).


CONCLUSIONS
Canadian patients with stable coronary artery disease did not meet several guideline-recommended secondary prevention targets, despite high use of evidence-based therapy, extensive financial coverage for these medications, and low physician underestimation of risk. Additional work is needed to identify and address the remaining barriers to effective risk factor control.
Terrence Donnelly Heart Centre, St Michael's Hospital, University of Toronto, Toronto, Ontario, Canada.
Sumeet
S
Gandhi
Terrence Donnelly Heart Centre, St Michael's Hospital, University of Toronto, Toronto, Ontario, Canada.
Paul
P
Dorian
Robertson Centre for Biostatistics, University of Glasgow, Glasgow, United Kingdom.
Nicola
N
Greenlaw
Montreal Heart Institute Coordinating Centre, Montreal Heart Institute, Université de Montréal, Montreal, Québec, Canada.
Jean-Claude
JC
Tardif
Recherche Clinique en Athérothrombose, Unité INSERM U698, Centre Hospitalier Bichat-Claude Bernard, Université Paris Diderot, Paris, France.
P Gabriel
PG
Steg
McGill University Health Centre, Montreal, Québec, Canada.
Thao
T
Huynh
Vancouver General Hospital, University of British Columbia, Vancouver, British Columbia, Canada.
Graham C
GC
Wong
Queen Elizabeth II Health Sciences Centre, Dalhousie University, Halifax, Nova Scotia, Canada.
Michael P
MP
Love
Institut de cardiologie et de pneumologie de Québec, Université Laval, Québec City, Québec, Canada.
Paul
P
Poirier
Terrence Donnelly Heart Centre, St Michael's Hospital, University of Toronto, Toronto, Ontario, Canada. Electronic address: goodmans@smh.ca.
Shaun G
SG
Goodman
D000368:Aged; D002170:Canada / Q000453:epidemiology; D003324:Coronary Artery Disease / Q000453:epidemiology / Q000628:therapy*; D019317:Evidence-Based Medicine / Q000379:methods*; D005260:Female; D005500:Follow-Up Studies; D014943:Global Health; D019983:Guideline Adherence; D006801:Humans; D008297:Male; D011379:Prognosis; D011446:Prospective Studies; D012042:Registries; D018570:Risk Assessment / Q000379:methods*; D012307:Risk Factors; D055502:Secondary Prevention / Q000379:methods*